“…Loose-fit Co-culture-based Sensitization Assay (LCSA): 48h treatment CD86 DCrc expression and cell viability by flow cytometry (Schreiner et al, 2007); (Schreiner et al, 2008); (Wanner and Schreiner, 2008); (Wanner et al, 2010); (Sonnenburg et al, 2012); (Sonnenburg et al, 2015); (Frohwein et al, 2016); (Frombach et al, 2017) Primary KC + PBMC with addition of cytokines cocktail after co-culture for 48h in serum free condition LCSA-ly: 48h treatment CD44, CD119, CD124 and IL-23R lymphocyte cell expression and cell viability by flow cytometry, extracellular release of IL-4, IFN-ɣ and IL-17 by ELISA (Frombach et al, 2018) NCTC2544 KC cell line + THP-1 cell line 24h treatment CD86, CD54, CCR7 and IL-8 co-culture expression by RT-qPCR (Meloni et al, 2010) HaCaT KC cell line + moDC 2 treatment protocols: either 1h treatment of HaCaT cell line, removal of treatment and co-culture with DC for 20h or 1h treatment of HaCaT cell line, removal of treatment, post-incubation for 20h and conditioned supernatant in contact with DC for 20h CD83 and CD86 moDC cell expression by flow cytometry (Matjeka et al, 2012) HaCaT KC cell line + primary dermal fibroblasts + MUTZ-LC 48h treatment Cell viability (Alamar Blue test), extracellular release of 27 cytokines using bio-plex assay and of IL-8 by ELISA (Lee et al, 2018) ELISA: enzyme-linked immunosorbent assay; moDC: monocytes-derived dendritic cell; MUTZ-LC: MUTZ-3 acute myeloid leukemia cell line differentiated into LC; PBMC: peripheral blood mononuclear cell; PI: propidium iodide…”